Related references
Note: Only part of the references are listed.Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia
Su W. Maung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Carla Casulo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Management of secondary immune deficiencies: what is the role of immunoglobulins?
Luc Mouthon et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis
B. Duxbury et al.
LUPUS (2013)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
D. E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
Inmaculada De La Torre et al.
RHEUMATOLOGY (2012)
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
Simone Lanini et al.
BMC MEDICINE (2011)
Does rituximab increase the incidence of infectious complications? A narrative review
Theodoros Kelesidis et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2011)
Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial
Clifton O. Bingham et al.
ARTHRITIS AND RHEUMATISM (2010)
Humoral Responses After Influenza Vaccination Are Severely Reduced in Patients With Rheumatoid Arthritis Treated With Rituximab
Sander van Assen et al.
ARTHRITIS AND RHEUMATISM (2010)
Acycloguanosine for the treatment of aplastic anaemia
Pietro Leoni et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Does rituximab aggravate pre-existing hypogammaglobulinaemia?
Lavanya Diwakar et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Late-Onset Neutropenia After Rituximab Treatment Case Series and Comprehensive Review of the Literature
Ofir Wolach et al.
MEDICINE (2010)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma
L. K. Hicks et al.
BONE MARROW TRANSPLANTATION (2009)
Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
Liat Vidal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2009)
The effects of rituximab on immunocompetency in patients with autoimmune disease
R. John Looney et al.
ARTHRITIS AND RHEUMATISM (2008)
Rituximab-related viral infections in lymphoma patients
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2007)
B cell depletion therapy in rheumatic disease
J. C. W. Edwards et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
F. Cabanillas et al.
ANNALS OF ONCOLOGY (2006)
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma
Mitsufumi Nishio et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Tolerability and safety of rituximab (MabThera®)
E Kimby
CANCER TREATMENT REVIEWS (2005)
Delayed-onset neutropenia associated with rituximab therapy
K Chaiwatanatorn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy
E Castagnola et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2003)
Share Paper
